相关临床试验
54
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1911
已完成
47
87.0%
尚未招募
2
3.7%
招募中
3
5.6%
Unknown
2
3.7%
暂无批准数据
- Swiss researchers engineered regulatory T cells with chimeric allergen receptors (CAlleRs) that specifically recognize birch pollen, reducing or preventing asthma symptoms in allergic mice. - The CAlleR Treg approach adapts CAR T cell technology from oncology to suppress, rather than activate, immune responses against common allergens. - In preclinical models, CAlleR Tregs decreased allergic inflammation, reduced mucus production, and improved lung function upon allergen re-exposure. - The study, published in JEM, provides proof-of-concept that this strategy could eventually treat severe allergic asthma and other allergies, including food allergens and house dust mites.
- 908 Devices completed the acquisition of Swiss-based NIRLAB AG for $15 million upfront, with up to $8 million in additional milestone payments over 20 months. - NIRLAB's AI-powered NIR spectroscopy platform enables handheld analysis of over 400 common drugs in seconds, with proven field performance of over one million analyses. - The acquisition expands 908 Devices' analytical portfolio and creates an end-to-end workflow solution for law enforcement agencies addressing the fentanyl and illicit drug crisis. - NIRLAB's technology can analyze drugs through plastic bags and glass, quantify drug purity in complex mixtures, and analyze cannabis THC and CBD percentages.
- Pilatus Biosciences has been granted foundational patents in Europe and Australia for its novel CD36-targeted immunotherapy approach that modulates regulatory T cells to enhance anti-tumor immunity. - The patent covers the company's first-in-class antibody program targeting CD36, a metabolic checkpoint on regulatory T cells that suppresses immune responses in the tumor microenvironment. - This intellectual property milestone strengthens Pilatus' position in metabolic checkpoint immunotherapy, with their lead program PLT012 designed to reprogram the tumor microenvironment and restore anti-tumor immunity. - The announcement coincides with the 2025 Nobel Prize in Physiology or Medicine being awarded for discoveries in regulatory T cell biology, highlighting the field's growing importance.
- Epitopea's CryptoMap platform identified 589 non-redundant tumor antigens in cutaneous melanoma and NSCLC, with only 1% derived from mutated sequences. - The platform discovered that 37% of identified tumor antigens were Cryptigens, which are immunogenic, shared among tumor samples, and could contribute to immune checkpoint blockade responses. - This research challenges the conventional focus on mutated tumor antigens and validates unmutated sequences as actionable targets for cancer immunotherapy. - The findings distinguish Epitopea's approach from other immunotherapy companies and support the development of accessible off-the-shelf RNA-based immunotherapies.
- New research from Swiss institutions demonstrates that age-related immune decline significantly reduces the effectiveness of CAR-T cell cancer therapy by impairing mitochondrial function and metabolism. - Scientists identified decreased levels of nicotinamide adenine dinucleotide (NAD) as the key factor behind reduced antitumor activity in CAR-T cells from older individuals. - Researchers successfully rejuvenated aged CAR-T cells by restoring NAD levels in preclinical models, suggesting potential strategies to improve immunotherapy outcomes in older cancer patients.
